One shot of Pfizer, AstraZeneca vax offers 60% protection ag
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A single dose of either the Pfizer or AstraZeneca Covid-19 vaccine offers around 60 percent protection against infection from SARS-CoV-2, the virus causing Covid-19, in adults aged 65 years and above, according to a new study. The study showed that the protective effect of a single dose of vaccination is evident from four weeks to at least seven weeks after vaccination, which provides some evidence to support extension of the interval between doses beyond three weeks, in line with UK policy.

"However, even beyond four weeks, a single vaccine dose does not eliminate infection risk, highlighting the continued importance of non-pharmaceutical measures to control transmission within long-term care facilities," said Madhumita Shrotri and Laura Shallcross, from the UCL Institute of Health Informatics.

The study will be critical to inform policy decisions regarding revaccination schedules in this vulnerable population and the disease control measures needed in the short, medium, and long term to protect long-term care facilities from future waves of SARS-CoV-2 infection, the team said.

The team analysed 10,412 care home residents aged 65 years and older from 310 facilities, with a median age of 86 years. Of these 1,155 residents had evidence of previous SARS-CoV-2 infection. A total of 9,160 residents received at least one vaccine dose during the study period, of whom 6,138 received AstraZeneca (ChAdOx1) and 3,022 received Pfizer (BNT162b2).

Between December 8, 2020 and March 15, 2021, there were 36,352 PCR tests carried out, with 1,335 PCR-positive infections detected. The risk of infection was 56 percent lower in vaccinated residents after 28 to 34 days, days, and 62 percent lower at 35-48 days. Similar effect sizes at 35-48 days were seen for the AstraZeneca vaccine and the Pfizer vaccine.